Abstract
In part II of this review, we describe the epidemiology and clinical consequences of vascular disease in patients with diabetes, and discuss the efficacy of risk factor modification and antiplatelet treatment. Specifically, evidence-based cardiovascular therapies are discussed through novel clinical insights on management of hyperglycaemia, hypertension, dyslipidaemia as well as platelet dysfunction. Recent trends in the incidence and outcomes of vascular disease in diabetes suggest that timely and effective implementation of therapies is making a favourable impact.
Keywords:
Diabetes; Medical therapy; Vascular disease.
MeSH terms
-
Antihypertensive Agents / therapeutic use
-
Atherosclerosis / drug therapy
-
Atherosclerosis / epidemiology
-
Coronary Disease / drug therapy
-
Coronary Disease / epidemiology
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Diabetes Mellitus, Type 2 / epidemiology
-
Diabetic Angiopathies / drug therapy*
-
Diabetic Angiopathies / epidemiology
-
Dyslipidemias / prevention & control
-
Global Health
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
-
Hyperglycemia / prevention & control
-
Hypertension / prevention & control
-
Hypoglycemic Agents / therapeutic use
-
Myocardial Reperfusion / methods
-
Peripheral Arterial Disease / drug therapy
-
Peripheral Arterial Disease / epidemiology
-
Platelet Aggregation Inhibitors / therapeutic use*
-
Prevalence
-
Risk Reduction Behavior
-
Stroke / drug therapy
-
Stroke / epidemiology
Substances
-
Antihypertensive Agents
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Hypoglycemic Agents
-
Platelet Aggregation Inhibitors